Evidence reviews – November 2024
The following documents contain the evidence that was used to develop the 2024 recommendations:
- Cognitive behavioural therapy
- Managing genitourinary symptoms (network meta-analyses)
- Managing genitourinary symptoms (breast cancer recurrence)
- Cardiovascular disease and stroke
- Breast cancer
- Endometrial cancer
- Ovarian cancer
- Dementia
- All-cause mortality
- Early menopause
The following documents contains the evidence that was used to develop the 2015 recommendations:
Other supporting evidence
- Supplement 1: Methods
- Supplement 2: Health economics
- Supplement 3: Acknowledgements
- Supplement 4: [B1] TSU NMA software code
- Supplement 5: [B1] TSU NMA software code inconsistency model
- Supplement 6: [B1] TSU NMA model fit statistics
- Supplement 7: [B1] TSU NMA sensitivity analyses forest plots
- Supplement 8: [B1] TSU NMA data extraction
- Supplement 9: [B1] data discae_short_biasadjust
- Supplement 10: [B1] data discae_short_fclass
- Supplement 11: [B1] data discomfort_biasadjust
- Supplement 12: [B1] data discomfort_fclass
- Supplement 13: [B1] data dryness_biasadjust
- Supplement 14: [B1] data dryness_fclass
- Supplement 15: [B1] data dyspar_biasadjust
- Supplement 16: [B1] data dyspar_fclass
- Supplement 17: [C] outcome data - RCTs
- Supplement 18: [C] outcome data: observational studies
- Supplement 19: Absolute calculations
- Economic model - Cost utility analysis: Interventions for bothersome genitourinary symptoms associated with the menopause
This page was last updated: